Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-24T11:54:15.773Z Has data issue: false hasContentIssue false
  • English
  • Français

Stimulant Use in Paediatric Acquired: Brain Injury: Evaluation of a Protocol

Published online by Cambridge University Press:  21 February 2012

Kathleen Bakker  and
Mary-Clare Waugh
Kathleen Bakker*
Affiliation:
Rehabilitation Department, New Children's Hospital, Westmead, Sydney. KathleB3@@nch.edu.au
Mary-Clare Waugh
Affiliation:
Rehabilitation Department, New Children's Hospital, Westmead, Sydney.
*
*Address for correspondence: Kathleen Bakker, Rehabilitation Department, New Children's Hospital, Mons Road, Westmead, NSW, 2145, Australia.
Get access

Abstract

Children with acquired brain injury (ABI) experience deficits in attentional skills such as, sustained attention, distractability and impulsivity, which have the potential to influence all aspects of their functioning. The use of central nervous system (CNS) stimulants is gaining increasing popularity in adult ABI literature. CNS stimulants have been successfully utilised in the management of attentional problems in attention deficit-hyperactivity disorder and are believed to have their therapeutic effect by modulating neurotransmitter function in the neocortex, an area of the brain implicated in the neurobehavioural sequelae of ABI. Research into the use of CNS stimulants in paediatric ABI reports contradictory findings. We present the case of LI a 7-year-old boy with a history of ABI who underwent a trial of stimulant medication for management of attentional deficits. The case is discussed with regard to the efficacy of the pharmacological intervention and the design of objective protocols for stimulant trials.

Type
Articles
Information
Brain Impairment , Volume 1 , Issue 1 , 01 May 2000 , pp. 29 - 36
Copyright
Copyright © Cambridge University Press 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)